Latest news
{{'2026-03-26T23:36:45Z' | dateFormatFilter}}
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
{{'2026-03-26T15:15:00Z' | dateFormatFilter}}
Resolutions from the Annual General Meeting of Novo Nordisk A/S
{{'2026-03-25T06:00:45Z' | dateFormatFilter}}
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
